Jake Shortt

High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma

Amanda Tey, James Schwarer, Robert Raffa, Emily Shi, Eldho Paul, Stephen Opat, Claire Dendle, Jake Shortt

Journal article  |  2023  |  EUROPEAN JOURNAL OF HAEMATOLOGY

OBJECTIVE: The infection risk in patients receiving ibrutinib, idelalisib or venetoclax for chronic lymphocytic leukaemia (CLL) or..

Distinct modulation of IFN gamma-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer

Simon J Hogg, Olga Motorna, Conor J Kearney, Emily B Derrick, Imran G House, Izabela Todorovski, Madison J Kelly, Magnus Zethoven, Kenneth D Bromberg, Albert Lai, Paul A Beavis, Jake Shortt, Ricky W Johnstone, Stephin J Vervoort

Journal article  |  2022  |  CLINICAL EPIGENETICS

BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temp..

Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.

Briony Shaw, Jake Shortt, Michael Low, Benjamin Rogers, Zane Kaplan, Pasquale Fedele, Gareth Gregory, Shahla Vilcassim, Michael Gilbertson, George Grigoriadis, Stephen Opat

Journal article  |  2022  |  Intern Med J

Coronavirus disease 2019 (COVID-19) infection in patients with haematological neoplasms has been associated with increased mortali..

Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).

Melissa Chen, Jake Shortt

Journal article  |  2022  |  Transfus Med Rev

Immune thrombotic thrombocytopenic purpura (iTTP) is a microangiopathic hemolytic anemia (MAHA) underpinned by autoreactivity agai..

Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Greg Hapgood, Maya Latimer, Sze Ting Lee, Bryone Kuss, Stephen Lade, Joshua WD Tobin, Duncan Purtill, Belinda A Campbell, H Miles Prince, Eliza A Hawkes, Jake Shortt, Dejan Radeski

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

Peripheral T-cell lymphomas (PTCL) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patie..

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

Emily Gruber, Joan So, Alexander C Lewis, Rheana Franich, Rachel Cole, Luciano G Martelotto, Amy J Rogers, Eva Vidacs, Peter Fraser, Kym Stanley, Lisa Jones, Anna Trigos, Niko Thio, Jason Li, Brandon Nicolay, Scott Daigle, Adriana E Tron, Marc L Hyer, Jake Shortt, Ricky W Johnstone, et al.

Journal article  |  2022  |  CELL REPORTS

Approximately 20% of acute myeloid leukemia (AML) patients carry mutations in IDH1 or IDH2 that result in over-production of the o..

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Aditya Tedjaseputra, James A Kuzich, Nisha Thiagarajah, Tse-Chieh Teh, Julia McClelland, Marzia Rahman, Rowena Brook, Chong Chyn Chua, Doen Ming Ong, Shuh-Ying Tan, Robin Filshie, Chun Yew Fong, Pasquale Fedele, Ashish Bajel, Jake Shortt, Andrew H Wei

Journal article  |  2022  |  LEUKEMIA & LYMPHOMA

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

Jonathan Wong, Emily Gruber, Belinda Maher, Mark Waltham, Zahra Sabouri-Thompson, Ian Jong, Quinton Luong, Sidney Levy, Beena Kumar, Daniella Brasacchio, Wendy Jia, Joan So, Hugh Skinner, Alexander Lewis, Simon J Hogg, Stephin Vervoort, Carmen DiCorleto, Micheleine Uhe, Jeanette Gamgee, Stephen Opat, et al.

Journal article  |  2022  |  LEUKEMIA

Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA)..

BET Inhibition Enhances TNF-Mediated Antitumor Immunity

Lisa C Wellinger, Simon J Hogg, Dane M Newman, Thomas Friess, Daniela Geiss, Jessica Michie, Kelly M Ramsbottom, Marina Bacac, Tanja Fauti, Daniel Marbach, Laura Jarassier, Phillip Thienger, Axel Paehler, Leonie A Cluse, Conor J Kearney, Stephin J Vervoort, Joseph A Trapani, Jane Oliaro, Jake Shortt, Astrid Ruefli-Brasse, et al.

Journal article  |  2022  |  CANCER IMMUNOLOGY RESEARCH

Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well..

P590: PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)

J Shortt, SY Tan, P Cannell, TF Ng, CY Fong, S Ramanathan, R Rajagopal, S Leitch, R Gasiorowski, C Grove, D Lenton, P Tan, C DiNardo, MT Ling, S Cheng, Y Liu, M Co, WY Chan, D Simpson, AH Wei

Journal article  |  2022  |  HemaSphere